Q1 2025 · 13F-HR
Commodore Capital LPholdings as filed
Filed 2025-05-15 · accession 0001831942-25-000005
$1.36B
Reported value
31
Positions
2025-03-31
Period end
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| N5749R100 | 2GH | MERUS N V | $188.3M | 13.9% | 4,472,840 | Common | SOLE |
| 670703107 | NUVL | NUVALENT INC | $131.6M | 9.69% | 1,855,000 | Common | SOLE |
| 29337E102 | ELVN | ENLIVEN THERAPEUTICS INC | $92.0M | 6.78% | 4,675,000 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $82.2M | 6.05% | 1,150,000 | Common | SOLE |
| 98420N105 | XENE | XENON PHARMACEUTICALS INC | $78.0M | 5.75% | 2,325,000 | Common | SOLE |
| G01767105 | ALKS | ALKERMES PLC | $64.4M | 4.74% | 1,950,000 | Common | SOLE |
| 00847X104 | AGIO | AGIOS PHARMACEUTICALS INC | $64.0M | 4.72% | 2,185,000 | Common | SOLE |
| 92243G108 | PCVX | VAXCYTE INC | $62.3M | 4.59% | 1,650,000 | Common | SOLE |
| 92337R101 | VERA | VERA THERAPEUTICS INC | $61.5M | 4.53% | 2,561,782 | Common | SOLE |
| 15117B202 | CLDX | CELLDEX THERAPEUTICS INC NEW | $58.1M | 4.28% | 3,200,000 | Common | SOLE |
| 80706P103 | SRRK | SCHOLAR ROCK HLDG CORP | $56.1M | 4.13% | 1,745,000 | Common | SOLE |
| 19240Q201 | COGT | COGENT BIOSCIENCES INC | $53.3M | 3.93% | 8,892,816 | Common | SOLE |
| 92790C104 | VRDN | VIRIDIAN THERAPEUTICS INC | $48.5M | 3.58% | 3,600,000 | Common | SOLE |
| 67080M103 | NRIX | NURIX THERAPEUTICS INC | $47.3M | 3.48% | 3,978,907 | Common | SOLE |
| 152309100 | CNTA | CENTESSA PHARMACEUTICALS PLC | $34.0M | 2.51% | 2,367,578 | Common | SOLE |
| 00773J202 | SYRE | SPYRE THERAPEUTICS INC | $32.1M | 2.36% | 1,988,084 | Common | SOLE |
| N69605108 | PHVS | PHARVARIS N V | $30.0M | 2.21% | 1,911,433 | Common | SOLE |
| 60255C885 | BRD1EUR | MIND MEDICINE MINDMED INC | $26.5M | 1.95% | 4,525,000 | Common | SOLE |
| 83422E204 | SLDB | SOLID BIOSCIENCES INC | $21.6M | 1.59% | 5,825,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $18.0M | 1.33% | 500,000 | Common | SOLE |
| 14147L108 | CRDF | CARDIFF ONCOLOGY INC | $16.9M | 1.25% | 5,384,616 | Common | SOLE |
| 687604108 | ORKA | ORUKA THERAPEUTICS INC | $14.6M | 1.07% | 1,419,714 | Common | SOLE |
| 45719W205 | IKT | INHIBIKASE THERAPEUTICS INC | $11.7M | 0.86% | 5,344,432 | Common | SOLE |
| 68622P109 | ORIC | ORIC PHARMACEUTICALS INC | $11.2M | 0.82% | 2,000,000 | Common | SOLE |
| 03770N101 | APGE | APOGEE THERAPEUTICS INC | $10.8M | 0.80% | 290,000 | Common | SOLE |
| 64135M105 | NGNE | NEUROGENE INC | $10.8M | 0.80% | 925,000 | Common | SOLE |
| 90240B106 | TYRA | TYRA BIOSCIENCES INC | $8.8M | 0.65% | 950,000 | Common | SOLE |
| G70077105 | PCSC | PERCEPTIVE CAP SOLUTIONS COR | $7.7M | 0.57% | 750,000 | Common | SOLE |
| 15102K100 | CELC | CELCUITY INC | $7.0M | 0.52% | 695,650 | Common | SOLE |
| 92840H400 | VTGN | VISTAGEN THERAPEUTICS INC | $3.9M | 0.29% | 1,575,000 | Common | SOLE |
| 05338F306 | AVTX | AVALO THERAPEUTICS INC | $3.9M | 0.29% | 483,000 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.